Breast Cancer Clinical Trial
Prospective Collection of Surplus Surgical Tumor Tissues and Pre-surgical Blood Samples
Summary
The study is intended to collect specimens to support the application of genome analysis technologies, including large-scale genome sequencing. This study will ultimately provide cancer researchers with specimens that they can use to develop comprehensive catalogs of genomic information on at least 50 types of human cancer. The study will create a resource available to the worldwide research community that could be used to identify and accelerate the development of new diagnostic and prognostic markers, new targets for pharmaceutical interventions, and new cancer prevention and treatment strategies. This study will be a competitive enrollment study conducted at multiple institutions.
Full Description
This study will enroll subjects diagnosed with various cancers and who are scheduled to undergo surgical treatment. Prior to scheduled surgery, subjects will be asked to donate a 10-20 ml blood sample. After surgery, surplus tissues (including tumor and adjacent normal tissues) not required for diagnosis will be collected. Subject clinical information will be collected, including basic demographic information, medical history, family history, current cancer history and treatment. After surgery, a final pathology report will be obtained for each subject's surgical specimen. In some instances and based on the cancer indications required, longitudinal data may also be collected at a frequency of every 6 months to once per year. Longitudinal data will include information on study subject survival and disease recurrence.
Eligibility Criteria
Inclusion Criteria:
Any adult age
Any sex
Able to provide consent for surplus tissue and/or blood donation
Diagnosed with one of the cancer indications listed below:
Scheduled to undergo surgical resection of tumor (exception for hematological cancers)
Have not yet received treatment for cancer
Exclusion Criteria:
Not diagnosed with required cancer indication
Not scheduled to undergo surgical resection of the tumor
Have already received cancer treatment (such as chemotherapy, radiation, surgery) for the current cancer or a previously diagnosed cancer
Not able to donate an adequate volume of blood to meet minimum requirements
CANCER INDICATIONS:
Bladder Cancer - Urothelial carcinoma - nonpapillary
Bladder Cancer - Urothelial carcinoma - papillary
Brain Cancer - Astrocytoma
Brain Cancer - Glioblastoma
Brain Cancer - Medulloblastoma
Breast Cancer - Ductal Carcinoma
Breast Cancer - Lobular Carcinoma
Cervical Cancer - Squamous Cell Carcinoma
Colorectal Cancer - Adenocarcinoma
Esophageal Cancer - Adenocarcinoma
Gastric Cancer
Head and Neck Cancer - Squamous Cell Carcinoma
Hematologic Cancer - Acute Lymphocytic Leukemia (ALL)
Hematologic Cancer - Acute Myeloid Leukemia (AML)
Hematologic Cancer - Chronic Lymphocytic Leukemia (CLL)
Hematologic Cancer - Diffuse Large B-cell Lymphoma
Hematologic Cancer - Multiple Myeloma (MM)
Hematologic Cancer - Non-Hodgkins Lymphoma (NHL)
Kidney Cancer - Papillary Carcinoma
Kidney Cancer - Renal cell Carcinoma
Liver Cancer - Hepatocellular Carcinoma
Lung Cancer - Adenocarcinoma
Lung Cancer - Squamous Cell Cancer
Melanoma
Pancreatic Cancer - Ductal Adenocarcinoma
Prostate Cancer - Adenocarcinoma
Sarcomas
Thyroid Cancer - Follicular Carcinoma
Thyroid Cancer - Papillary Carcinoma
Uterine Cancer - Endometrial Carcinoma
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Seattle Washington, 98104, United States
How clear is this clinincal trial information?
